Serum Contactin-1 in CIDP: A Cross-Sectional Study.

Autor:	Wieske L; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands. l.wieske@amsterdamumc.nl., Martín-Aguilar L; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Fehmi J; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Lleixà C; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Koel-Simmelink MJA; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Chatterjee M; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., van Lierop Z; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Killestein J; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Verhamme C; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Querol L; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Rinaldi S; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Teunissen CE; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands., Eftimov F; From the Department of Neurology and Neurophysiology (L.W., C.V., F.E.), Amsterdam Neuroscience, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands; Neuromuscular Diseases Unit (L.M.-A., C.L., L.Q.), Department of Neurology, Hospital de La Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain; Department of Clinical Neurosciences (J.F., S.R.), West Wing, John Radcliffe Hospital, Oxford, United Kingdom; Neurochemistry Lab (M.J.A.K.-S., C.E.T.), Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; and Department of Neurology (M.C., Z.L., J.K.), Amsterdam Neuroscience, Amsterdam UMC, Location VU Medical Center, Amsterdam, the Netherlands.
Jazyk:	angličtina
Zdroj:	Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2021 Jul 20; Vol. 8 (5). Date of Electronic Publication: 2021 Jul 20 (Print Publication: 2021).
DOI:	10.1212/NXI.0000000000001040
Abstrakt:	Objective: To investigate whether serum levels of contactin-1, a paranodal protein, correlate with paranodal injury as seen in patients with CIDP with antibodies targeting the paranodal region. Methods: Serum contactin-1 levels were measured in 187 patients with CIDP and 222 healthy controls. Paranodal antibodies were investigated in all patients. Results: Serum contactin-1 levels were lower in patients (N = 41) with paranodal antibodies compared with patients (N = 146) without paranodal antibodies ( p < 0.01) and showed good discrimination between these groups (area under the curve 0.84; 95% CI: 0.76-0.93). Conclusions: These findings suggest that serum contactin-1 levels have the potential to serve as a possible diagnostic biomarker of paranodal injury in CIDP. Classification of Evidence: This study provides class II evidence that serum contactin-1 levels can discriminate between patients with CIDP with or without paranodal antibodies with a sensitivity of 71% (95% CI: 56%-85%) and a specificity of 97% (95% CI: 83%-100%). (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu